Please do not leave this page until complete. This can take a few moments.
Massachusetts Attorney General Maura Healey, who sued OxyContin manufacturer Purdue Pharma, wouldn't comment Wednesday on reports of a possible $12 billion settlement that would resolve thousands of lawsuits targeting the company for its role in the opioid epidemic.
Purdue Pharma and its owners, the Sackler family, are reportedly in talks with state attorneys general and others around settling more than 2,000 lawsuits against the company. Purdue and the Sacklers are expected to settle for $10 billion to $12 billion, according to reports by multiple media outlets including The New York Times, The Washington Post and NBC News.
Healey declined to comment Wednesday on the news of a possible settlement, as did Gov. Charlie Baker. Healey's office did not respond to questions about whether Healey, who has not held a public event in more than a month, has been among the group of state attorneys general meeting in Cleveland to discuss a settlement.
In June 2018, Healey filed the first state lawsuit against individual members of the Sackler family as well as Purdue Pharma, alleging that they "engaged in a deadly, deceptive scheme to sell opioids in Massachusetts" and profited from the drug epidemic they helped create.
[Related: Worcester pharmacies stocked 49 million prescription opioids in years leading up to crisis]
Healey announced the lawsuit in June 2018 while standing alongside Baker and six poster boards that displayed the first names of the 11,169 people in Massachusetts who died from opioid overdoses from 2008 through 2017.
Healey's complaint alleges that Purdue "created the epidemic and profited from it through a web of illegal deceit" by deceiving doctors and patients to get more people on their drugs, at "higher and more dangerous doses" and for longer periods of time, as well as by deploying falsehoods to keep patients away from "safer alternatives."
A total of 671 Massachusetts residents who filled prescriptions for Purdue opioids since 2009 later died of an opioid overdose, according to the suit. According to Healey's office, Purdue sent sales representatives to Massachusetts doctors, offices, clinics and hospitals more than 150,000 times since 2008.
"You would think that at some point in time, the people who are at the heart of this would realize the pain and the agony that they had created and step back," Baker said last year when the suit was announced. "They chose to do just the opposite and double down, and I can't tell you how much I appreciate the work that's been done by the attorney general to put these people where they belong, which is in a courtroom and in a deposition and in a process that will force them to own up to the decisions they made in the wreckage they left behind."
[Related: Mass. opioid deaths down 11% this year]
Under the settlement framework described to NBC News and later to the New York Times, the Connecticut-based Purdue Pharma would file for Chapter 11 bankruptcy and restructure itself as a "public beneficiary trust." All future profits from the company would flow to the plaintiffs, namely state and local governments that have sued Purdue.
The company would also provide the addiction treatment drugs that it has under development to the public at no cost, the Times reported. In addition, the Sackler family would relinquish ownership and control of Purdue Pharma and pay an additional $3 billion of their own money towards the settlement.
Purdue Pharma on Tuesday said it is "prepared to defend itself vigorously in the opioid litigation" but is discussing a settlement because it "sees little good coming from years of wasteful litigation and appeals" and "the people and communities affected by the opioid crisis need help now."
"Purdue believes a constructive global resolution is the best path forward, and the company is actively working with the state attorneys general and other plaintiffs to achieve this outcome," the company said in a statement.
A federal judge in Cleveland is overseeing more than 2,000 lawsuits filed against the Sacklers and Purdue. About 10 states have been involved in negotiations in Cleveland, the Times reported.
Though Healey's office would not say whether she has been part of the talks, Connecticut Attorney General William Tong "was part of a group of attorneys general who met last week in Cleveland, where outlines of a deal were discussed," the outlet CT Mirror reported.
Stay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Sign upWorcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
SubscribeWorcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
See Digital EditionStay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Worcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
Worcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments